Interventions for restoring patency of occluded central venous catheter lumens

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 12, 2012, Pages

  van Miert, Clare ^a   Hill, Rebecca ^a   Jones, Leanne ^b  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; CATHETER; CENTRAL VENOUS CATHETERIZATION; CHILD; EQUIPMENT; HUMAN; INSTRUMENTATION; META ANALYSIS; REVIEW; THROMBOSIS;

ADULT; ANTICOAGULANTS; CATHETERIZATION, CENTRAL VENOUS; CATHETERS; CHILD; EQUIPMENT FAILURE; HUMANS; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84864053614     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007119.pub2     Document Type: Review

References (71)

1. Deitcher SR, Fraschini G, Himmelfarb J, Schuman E, Smith TJ, Schulz GA, et al. Dose-ranging trial with a recombinant urokinase for occluded central venous catheters in oncology patients. Journal of Vascular Interventional Radiology 2004;15:575-9. [PUBMED: 15178717]x-wiley/crsRef/2647881
2. Fink JM, Capozzi D, Shermock KM, Militello MA, Huston T, Kalaycio M, et al. Alteplase for central catheter clearance: does 1mg/ml versus 2mg/2ml. The Annals of Pharmacotherapy 2004;38:351. [PUBMED: 14742778]x-wiley/crsRef/2647883
3. Haire WD, Atkinson JB, Stephens LC, Kotulak GD. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters:a double-blinded, randomized trial. Thrombosis and Haemostasis 1994;72(4):543-7. [PUBMED: 7878629]x-wiley/crsRef/2647885
4. Haire WD, Deitcher SR, Mullane KM, Jaff MR, Firszt CM, Schulz GA, et al. Recombinant urokinase for restoration of patency in occluded central venous access devices: A double-blind, placebo-controlled trial. Thrombosis and Haemostasis 2004;92:575-82. [PUBMED: 15351854]x-wiley/crsRef/2647887
5. Horne MK III, Mayo DJ. Low-dose urokinase infusions to treat fibrinous obstruction of venous access devices in cancer patients. Journal of Clinical Oncology July;15(7):2709-14. [PUBMED: 9215844]x-wiley/crsRef/2647889
6. Moll S, Kenyon P, Bertoli L, De Maio J, Homesley, Deitcher SR. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. Journal of Clinical Oncology 2006;24(19):3056-60. [PUBMED: 16809729]x-wiley/crsRef/2647891
7. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial - the cardiovascular thrombolytic to open occluded lines (COOL) efficacy trial. Journal of Vascular Interventional Radiology 2001;12:951-5. [PUBMED: 11487675]x-wiley/crsRef/2647893
8. Semba CP, Deitcher SR, Li X, Resnansky L, Tu T, McCluskey ER, Cardiovascular Thrombolytic to Open Occluded Lines Investigators. Treatment of occluded central venous catheters with alteplase: results in 1,064. Journal of Interventional Radiology 2002;13:1199-205. [PUBMED: 12471182]x-wiley/crsRef/2647894
9. Barrett PJ, Lester RL. Heparin versus saline flushing solutions in a small community hospital. Hospital Pharmacy 1990;25:115-9. [PUBMED: 10103699]x-wiley/crsRef/2647896
10. Lawson M, Bottino JC, Hurtubise MR, McCredie KB. The use of urokinase to restore the patency of occluded central venous catheters. The American Journal of Intravenous Therapy & Clinical Nutrition 1982;9(9):29-32. x-wiley/crsRef/2647898
11. Molinari AC, Haupt R, Saracco P, Di Marco M, Castagnola E, Fratino G. Urokinase for restoring patency of malfunctioning or blocked central venous catheters in children with hemato-oncological diseases. Supportive Cancer Care 2004;12:840-3. [PUBMED: 15365798]x-wiley/crsRef/2647900
12. Ng R, Li X, Tu T, Semba C. Alteplase for treatment of occluded peripherally inserted central catheters: safety and efficacy in 240 patients. Journal of Vascular and Interventional Radiology 2004;15:45-9. [PUBMED: 14709686]x-wiley/crsRef/2647902
13. Owens L. Reteplase for clearance of occluded venous catheters. American Journal of Health System Pharmacy 2002;59:1638-40. [PUBMED: 12224345]x-wiley/crsRef/2647904
14. No authors listed. Urokinase-streptokinase embolism trial: phase 2 results. A cooperative study. JAMA 1974;229(12):1606-13. [PUBMED: 4408392]x-wiley/crsRef/2647906
15. Svoboda P, Barton RP, Barbarash OL, Butylin AA, Jacobs BR, Lata J, et al. Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: A multiple-centre international trial. Critical Care Medical 2004;32(10):1990-6. [PUBMED: 15483405]x-wiley/crsRef/2647908
16. Zeitler E. The action of various drugs in the prevention of re-occlusion following Dotter's catheter disobliteration [Wirkung verschiedener Medikamente zur Verhütung des Reverschlusses nach Katheter-Desobliteration nach Dotter]. Die Medizinische Welt 1976;27(28):1377-80. [PUBMED: 785147]x-wiley/crsRef/2647910
17. Gabrail N, Sandler E, Charu V, Anas N, Lim E, Blaney M, et al. TROPICS 1: a phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in dysfunctional catheters. Journal of Vascular and Interventional Radiology December 2010;21(12):1852-8. x-wiley/crsRef/2647912
18. Levine R. A study of tenecteplase for restoration of function in dysfunctional central venous catheters. ClinicalTrials.gov Nov 2006. x-wiley/crsRef/2647914
19. Muller C, Jacquier A, Varoquaux A, Cohen F, Louis G, Gaubert JY, et al. Urokinase in the management of occluded PICC lines. Journal of Radiologie March 2010;3 C1:287-91. [PUBMED: 20508559]x-wiley/crsRef/2647916
20. Authors not reported. Trial of a novel fibrinolytic (alfimeprase) to clear thrombosed vascular access devices. ClinicalTrials.gov 21st November 2003. x-wiley/crsRef/2647918
21. [No authors listed] 1970. Urokinase Pulmonary Embolism Trial: Phase I Results. JAMA 1974;229(12):1606. [PUBMED: 5536580]
22. Atkinson JB, Bagnall HA, Gomperts E. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters. Journal of Parenteral and Enteral Nutrition 1989;14(3):310-11. [PUBMED: 2112648]
23. Barnacle A, Arthurs OJ, Roebuck D, Hiorns MP. Malfunctioning central venous catheters in children: a diagnostic approach. Pediatric Radiology 2007;38(4):363-78. [PUBMED: 2292495]
24. Bertina RM. Introduction: hypercoagulable states. Seminars in Hematology 1997;34(3):167-9. [PUBMED: 9241703]
25. Blaney M, Shen V, Kerner JA, Jacobs BR, Gray S, Armfield J, Semba CP. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open label, single arm study (the cathflo activase pediatric study). Journal of Vascular Interventional Radiology 2006;17:1745-51. [DOI: 10.1097/01.RVI.0000241542.71063.83]
26. British Medical Association. In: Michael Peters editor(s). The British Medical Dictionary. London: Dorling Kindersley, 2002. [ISBN 0-7513-3383-2]
27. Bouza E, Perez-Molina J, Munoz P (ESGNI) obotCGotESGoNI. Report of ESGNI-001 and ESGNI-002 studies. Bloodstream infections in Europe. Clinical Microbiology and Infection 1999;5:2S1-2S12. [DOI: 10.1111/j.1469-0691.1999.tb00536.x]
28. Breux CW, Duke D, Georgeson KE, Mestre JR. Calcium phosphate crystal occlusion of central venous catheters used for total parenteral nutrition in infants and children prevention and treatment. Journal of Pediatric Surgery 1987;22(9):829-32. [DOI: 10.1016/s0022-3468(87)80648-6]
29. Busseires JF, Therrien R, David M, Leclair JP, Harel F. Efficacy of urokinase and alteplase to reopen occluded central venous catheters in children. Journal of Pharmacology Technology 2001;17:95-97.
30. Chaiyakunapruk N, Veenstra D, Lipsky B, Saint S. Chlorhexidine compared with povidine-iodine solution for vascular catheter-site care: A meta-analysis. Annals of Internal Medicine 2002;136(11):792-801. [PUBMED: 12044127]
31. Chesler L, Feusner JH. Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters. Journal of Pediatric Hematology/Oncology 2002;24(8):653--56. [PUBMED: 12439038]
32. Choi M, Masicotte P, Marzinotto V, Chan AK, Holmes JL, Andrew M. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study. Journal of Pediatrics 2001;139:152-6. [DOI: 10.1067/mpd.2001.115019]
33. Cook D, Randolph A, Kernerman P, Cupido C, King D, Soukup C, Brun-Buisson C. Central venous catheter replacement strategies: A systematic review of the literature. Critical Care Medical 1997;25(8):1417-24. [PUBMED: 9267959]
34. Deitcher SR, Fesen MR, Kiproff PM, Hill PA, Li X, McCluskey ER, Semba CP. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. Journal of Clinical Oncology 2002;20(1):317-24. [PUBMED: 11773185]
35. Duffy LF, Kerzner B, Gebus V, Dice J. Treatment of central venous catheter occlusions with hydrochloric acid. Journal of Pediatrics 1989;114(6):1002-4. [PUBMED: 2498489]
36. Elliot TS. Line-associated bacteraemias. Communicable Disease Report. CDR review 1993;3:R91-6. [PUBMED: 7693163]
37. Goodwin ML. Using sodium bicarbonate to clear a medication precipitate from a central venous catheter. Journal of Vascular Access Networks 1991;1:23.
38. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians?. BMJ 2008;336:995-8. [PUBMED: 18456631]
39. Hadaway L. Major thrombotic and nonthrombotic complications. Journal of Intravenous Nursing 1998;21(5):s143-59. [PUBMED: 9814289]
40. Hamilton H. Care improves whilst costs reduce. The clinical nurse specialist in total parenteral nutrition. Professional Nurse 1993;8(6):592-8. [PUBMED: 8511159]
41. Hardy G, Ball P. Clogbusting: time for a concerted approach to catheter occlusions?. Current Opinion in Clinical Nutrition and Metabolic Care 2005;8(3):277-83. [PUBMED: 15809530]
42. Hardy G, Ball P. Avoiding catheter complications with lipid containing parenteral nutrition. British Journal of Intensive Care 2006;16(2):64-7.
43. Herbst S, Kaplan LK, McKinnon BT. Vascular access devices: managing related complications in home infusion. Infusion 1998;4 Suppl:1-32.
44. Higgins JP, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60. [PUBMED: 12958120]
45. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
46. Higgins JPT, Altman DG (editors). Chapter 16: Special topics in statistics. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration, 2011.
47. Hockenhull JC, Dwan K, Boland A, Smith G, Bagust A, Dundar Y, et al. The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation. Health Technology Assessment 2008;12(12):1-151. [PUBMED: 18405471]
48. Jacobs BR, Haygood M, Hingl J. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children. Journal of Pediatrics 2001;139:593-6. [PUBMED: 11598611]
49. Jacobs BR. Central venous catheter occlusion and thrombosis. Critical Care Clinical 2003;19:489-514. [PUBMED: 12848317]
50. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6. [PUBMED: 11440947]
51. Liu CY, Jain V, Shields AF, Heilbrun LK. Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer. Journal of Vascular Interventional Radiology 2004;15:39-44. [DOI: 10.1097/01.RVI.0000106385.63463.EC]
52. Mammen EF. Pathogenisis of venous thrombosis. Chest 1992;102(6):640s-4s. [PUBMED: 1451539]
53. McKinnon BT. Techniques and Procedures FDA Safety Alert: Hazards of precipitation associated with parenteral nutrition. Nutrition in Clinical Practice 1996;11(3):59-65. [PUBMED: 8788339]
54. Moureau N, Poole S, Murdock MA, Gray SM, Semba CP. Central venous catheters in home infusion care: Outcomes analysis in 50,470 patients. Journal of Vascular and Interventional Radiology 2002;10(13):1009-16. [PUBMED: 12397122]
55. Nazario R, Delorenzo LJ, McGuire GP. Treatment of venous thromboembolism. Cardiology in Review 2002;10(4):249-59. [PUBMED: 12144736]
56. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
57. Sando K, Fujii K, Tanaka K, Chen H, Yoshida Y, Iiboshi R, et al. Lock method using sodium hydroxide solution to clear occluded central venous access devices. Clinical Nutrition 1997;16:185-8. [PUBMED: 16844597]
58. Schindler J, Bona RD, Chen HH, Feingold JM, Edwards RL, Tutschka PJ, Bilgrami S. Regional thrombolysis with urokinase for central venous catheter-related thrombosis in patients undergoing high-dose chemotherapy with autologous blood stem cell rescue. Clinical and Applied Thrombosis/Hemostasis 1999;5(1):25-9. [PUBMED: 10725979]
59. Schultz KF, Altman DG, Moher D for the CONSORT Group. CONSORT 2010 Statetment: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine 2010;152(11):1-8. [PUBMED: 20335313]
60. Shen V, Li X, Murdock M, Resnansky L, McClusky ER, Semba CP. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients. Journal of Pediatric Hematology/Oncology 2003;25(1):38-45. [PUBMED: 12544772]
61. Shulman RJ, Reed T, Pitre D. Use of hydrochloric acid to clear obstructed central venous catheters. Journal of Parenteral and Enteral Nutrition 1988;12:510. [PUBMED: 3184423]
62. Simon A, Bode U, Leiber K, Beutel K, Fleischhack G. Review and update of the use of urokinase in the prevention and management of CVAD-related complications in pediatric oncology patients. American Journal of Infection Control 2008;36:54-8. [DOI: 10.1016/j.ajic.2007.02.007]
63. Stephens LC, Haire WD, Kotulak GD. Are clinical signs accurate indicators of the cause of central venous catheter occlusion?. Journal of Parenteral and Enteral Nutrition 1995;19(1):75-79. [PUBMED: 7658605]
64. Wachs T. Urokinase administration in pediatric patients with occluded central venous catheters. Journal of Intravenous Nursing 1990;13(2):100-2. [PUBMED: 2313458]
65. Walshe L, Malak S, Eagan J, Sepkowitz K. Complication rates amongst cancer patients with peripherally inserted central catheters. Journal of Clinical Oncology 2002;20:3276-81. [PUBMED: 12149302]
66. Authors unknown. Websters New World Medical Dictionary. 3rd Edition. Hoboken, NJ, USA: Wiley Publishing, Inc, 2009. [9780470189283]
67. Werlin SL, Lausten T, Jessen S, Toy L, Norton A, Dallman L, et al. Treatment of central venous catheter occlusions with ethanol and hydrochloric acid. Journal of Parenteral and Enteral Nutrition 1995;5:416-8. [PUBMED: 8577023]
68. Wheeler S, Maki S, Stolz S, Mermal LA. Prevention of central venous catheter related blood stream infection by use of an antiseptic-impregnated. A randomized controlled trial. Annals of Internal Medicine 1997;127(4):257-6. [MEDLINE: 9265424]
69. Whigham CJ, Lindsey JI, Goodman CJ, Fisher RG. Venous port salvage utilizing low dose tPA. Cardiovascular Interventional Radiology 2002;25:513-6. [DOI: 10.1007/s00270-002-2615-4]
70. Wingerter L. Vascular access device thrombosis. Clinical Journal of Oncology Nursing 2003;7(3):345-8. [PUBMED: 12793345]
71. Yacopetti N. Central venous catheter-related thrombosis: A systematic review. Journal of Infusion Nursing 2008;31(4):241-8. [PUBMED: 18641488]